💊 दवाएँ A-Z 🧬 लक्ष्य 🛠 उपकरण 📚 मार्गदर्शिकाएँ
सभी दवाएँ दवा वर्ग चिकित्सीय क्षेत्र दुष्प्रभाव
मार्गदर्शिकाएँ शब्दकोश समयरेखा
तुलनाएँ दवाओं की यात्राएँ दवा परिवार
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Rotigotine

CHEMBL1303 Phase 4 अनुमोदित Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
315.5 g/mol
LogP
4.9
Phase
4

Rotigotine is a non-ergoline dopamine receptor agonist delivered transdermally, used primarily for the treatment of Parkinson's disease and restless legs syndrome, with investigational applications in Alzheimer's disease and epilepsy. It acts as an agonist at D1, D2, and D3 dopamine receptors, as well as alpha-adrenergic and serotonin receptors, restoring dopaminergic tone in the striatum. Continuous transdermal delivery provides stable plasma levels, reducing motor fluctuations.

आणविक भार

315.5000 g/mol

LogP

4.90

TPSA

51.70 Ų

लिपिंस्की RO5

उत्तीर्ण

चिकित्सीय क्षेत्र

अल्ज़ाइमर रोग जनरलाइज़्ड एंग्ज़ाइटी डिसऑर्डर पार्किंसन रोग मल्टीपल स्क्लेरोसिस माइग्रेन मिर्गी (एपिलेप्सी) स्ट्रोक

क्रिया का तंत्र

Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

तंत्र

Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

2D संरचना

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1

                

                

                
                

                    
InChI

                    
InChI=1S/C19H25NOS/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21/h3-7,13,16,21H,2,8-12,14H2,1H3/t16-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C19H25NOS

                    

                    
                    

                        
HBD / HBA

                        
1 / 3

                    

                    
                    

                        
घूर्णनीय बंधन

                        
6

                    

                    
                    
                    

                        
भारी परमाणु

                        
22

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
अक्सर पूछे जाने वाले प्रश्न

                

                    
                    

                        
                        

                            
Rotigotine is a non-ergoline dopamine receptor agonist delivered transdermally, used primarily for the treatment of Parkinson's disease and restless legs syndrome, with investigational applications in Alzheimer's disease and epilepsy. It acts as an agonist at D1, D2, and D3 dopamine receptors, as well as alpha-adrenergic and serotonin receptors, restoring dopaminergic tone in the striatum. Continuous transdermal delivery provides stable plasma levels, reducing motor fluctuations.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Rotigotine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1303.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 59227.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
चिकित्सा अस्वीकरण

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.